Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Whether for therapeutics, diagnostics, or research, ProteoGenix delivers custom antibody production services tailored to your specific application. With our exclusive performance guarantee, antibodies are validated directly in your laboratory, ensuring you only move forward with antibodies that truly work in your system.
Tool
Answer a few questions and find the technology that best fits your target, application and timeline.
Over 20 years of expertise in custom antibody production.
Depending on your project, we guarantee either a defined number of binders or functional performance in your target application (validated in your lab).
Antibodies are tested both in-house by ProteoGenix and directly in your laboratory, ensuring reliable real-world performance in your experimental conditions.
Human, mouse, humanized mouse, rat, rabbit, dog, cat, camelids, and all major antibody formats including IgG, Fab, scFv, and VHH, optimized for diverse applications.
You retain complete IP rights and full ownership over all generated antibodies generated within your project.
Our diversified technologies enable alternative and complementary strategies when standard approaches fail.
From antigen design to stable cell line development, we support the entire workflow to reduce multi-vendor friction.
AIxplore® de novo antibody generation
Receive your antibody sequence in as little as 3 days.
Early optimization for affinity, stability and developability.
Rapid generation of monoclonal antibody sequences against a broad range of targets.
Experimental validation to support candidate selection.
A fully animal-free antibody discovery process from design to validation.
Risk-mitigated antibody development
At ProteoGenix, we operate as an extension of your laboratory. Like you, our objective is to minimize development risk and maximize the probability of success from the earliest stages of the project.
To achieve this, we integrate multiple risk-mitigation strategies directly into our custom antibody development workflows.
Depending on your application, we guarantee either a defined number of binders or functional performance in your final assay.
This gives your project a clear success framework from the beginning.
Antibodies are screened directly in the assays relevant to your project, so selection is aligned with your real experimental needs.
Candidate antibodies are validated internally by ProteoGenix scientists and can also be tested directly in your own laboratory environment.
This confirms real-world performance under your experimental conditions.
Our workflows include predefined decision points that allow you to stop, continue, or redirect the project at critical stages.
This helps you maintain control over timelines, budget and scientific direction.
If a project does not initially succeed, ProteoGenix can help you protect the value of the program through guarantees and alternative discovery strategies.
You can activate your project guarantee according to the agreed project framework.
We can implement an alternative strategy using one of our four monoclonal antibody discovery platforms to maximize the chances of obtaining successful candidates.
| Hybridoma | Phage display | Single B cell screening | De novo antibody generation
NEW! |
Polyclonal antibodies | |
|---|---|---|---|---|---|
| Species | Mouse/Rat |
|
|
|
|
| Formats | IgG/Fab/scFv | IgG/Fab/scFv/VHH | IgG/Fab/scFv | IgG/Fab/scFv/VHH | IgG/VHH |
| Guarantees | Applications guaranteed :
|
3 binders guaranteed (can vary depending on the protocol) | 3 unique clones or application guarantee | Project-dependent | ELISA titer 1:64000 |
| Applications | Ideal for diagnostic and research (coupled to application validated protocols) | Ideal for therapeutic (can be coupled to specific protocols such as neutralizing, counter-screening or cross-reacting and human or VHH libraries) and veterinary applications (coupled to cat, dog and swine libraries) | Ideal for therapeutic (coupled to humanized mice) and diagnostic applications (coupled to rabbit immunization and application guaranteed protocols) | Very interesting for therapeutic antibody development as developability is taken into account since the very beginning of the project (can be coupled to specific protocols such as neutralizing, counter-screening or cross-reacting and human or VHH libraries) | Mainly for diagnostic and research applications |
| Package content |
|
|
|
|
|
| Deliverables |
|
|
|
|
10µl of pre-immune serum 300-500µl of antiserum or 10-100 µg of purified antibodies (if purification option included) |
| Lead time | From 7 weeks | From 3 weeks | From 8 weeks | From 3 days | From 9 weeks |
| Price |
Project-dependent pricing Get a quote |
Project-dependent pricing Get a quote |
Project-dependent pricing Get a quote |
Project-dependent pricing Get a quote |
From 310€ |
A leading antibody development company
ProteoGenix is a specialized provider of custom antibody production services supporting biotechnology companies, pharmaceutical developers, and academic research laboratories worldwide. Our integrated platform combines antibody discovery, sequencing, engineering, and recombinant production to accelerate antibody development from concept to validated candidate.
A dedicated PhD expert oversees your entire custom antibody development project, ensuring continuity and precision at every stage. From antigen design to custom cell line development, our services operate in full synergy, enabling us to manage all aspects of your project seamlessly. With more than 6000 antibodies developed, our expertise allows us to deliver solutions suited to any application. To keep you in full control, we have integrated multiple Go/No-Go checkpoints throughout the process, allowing informed decisions at every step.
Thanks to our accelerated workflows, get your custom antibodies in less than 4 weeks. This rapid turnaround helps you reduce development delays and reach your next milestone without interruption.
Outsourcing your antibody development can seem risky, that is why ProteoGenix offers the strongest guarantees of the market. De-risk your project for a seamless project.
With ProteoGenix, you retain complete ownership and exclusive rights to all antibodies developed. No shared IP, no restrictions, and full freedom to use your results as you wish.
N Tirado et al., CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol 18, 69 (2025).
https://doi.org/10.1186/s13045-025-01715-0
R López-Aladid et al., Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies. Sci Rep 15, 16269 (2025).
https://doi.org/10.1038/s41598-025-00555-9
M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024).
https://doi.org/10.3389/fimmu.2024.1520103
H Sihto et al., Phosphodiesterase 3 A expression in gastrointestinal stromal tumors. Virchows Arch 487, 983–991 (2025).
https://doi.org/10.1007/s00428-025-04150-1
Trusted by Research, Biotech, and Academic Teams Worldwide